Close Menu

financial guidance

Rapid immunoassay product revenues — including sales from the firm's QuickVue, Sofia, and Eye Health products — rose 40 percent year over year.

Total sample-to-answer molecular product revenue for the first quarter of 2018 was $16.5 million, representing 49 percent growth.

Although revenues from the firm's global diagnostics business were down 6 percent year over year, molecular diagnostic product revenues were up 6 percent.

In 2018, the company expects to place between 140 and 170 new ePlex analyzers, and an annuity per ePlex in the $100,000 to $120,000 range.

The company said it also saw record cash collections in the quarter despite challenges caused by regulatory change.

The company said revenues in its diagnostics business unit rose 62 percent during the quarter.

The company said test volume rose 87 percent to 186,000 during the quarter.

Lifted by a strong flu season, Cobas Liat PCR placements reached 1,500 systems in the US. Globally, year-over-year sales for the point-of-care system grew 262 percent.

The company said it had a large uptick in testing revenues during the quarter, including for its AlloSure kidney transplant test, which was launched in October.

Guidance for 2018 placements of ePlex respiratory testing systems is lower than analysts’ estimates, but the firm communicated remedies for adoption challenges.

Pages

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.